KLX 171 Pill — WHITE ROUND, 12mm — Fenofibrate

No photo available
View full Fenofibrate profile
ImprintKLX / 171
ColourWHITE
ShapeROUND
Size12
StrengthFenofibrate 160 mg
Dosage formTablet, Coated
ManufacturerKaralex Pharma LLC
NDC42043-171
Schedule—
Availability—
IngredientsFenofibrate[Fenofibrate]

What does this imprint mean?

The imprint "KLX 171" is a code stamped or printed on the tablet or capsule by the manufacturer, used to identify the drug, its strength and the maker.

Active ingredient

Fenofibrate

Uses and warnings

No boxed warning. Contraindicated in "severe renal impairment, including those with end-stage renal disease," "active liver disease," "pre-existing gallbladder disease," and known hypersensitivity to fenofibrate or fenofibric acid. Major warnings include risk of "serious drug-induced liver injury, including liver transplantation and death"; "myopathy and rhabdomyolysis," particularly with concomitant statin use or renal impairment; increased serum creatinine; cholelithiasis; pancreatitis; venous thromboembolism; and potentiated anticoagulant effect with coumarin-type drugs requiring dose adjustment and monitoring.

Fenofibrate is indicated as adjunctive therapy to diet to reduce "triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (TG greater than or equal to 500 mg/dL)" and to reduce elevated "low-density lipoprotein cholesterol (LDL-C)" in adults with primary hyperlipidemia when statin therapy is not appropriate. The label includes an important limitation of use: "Fenofibrate did not reduce coronary heart disease morbidity and mortality in two large, randomized controlled trials of patients with type 2 diabetes mellitus."

Read the full drug profile →

How to identify this pill

Similar-looking pills

Other pills of Fenofibrate

Official references

Source: FDA Structured Product Label via NLM Pillbox archive (retired 2021); source file 5d0a9228-18e6-4bb7-b9e5-58f41fdcb22e.xml